Vericel Corporation — FY2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed February 25, 2020. The filing is an annual report, not a quarterly Form 10-Q, although it provides unaudited quarterly data. Vericel is a commercial-stage biopharmaceutical company focused on autologous cell therapies for sports medicine and severe burn care. Its marketed U.S. products are MACI for knee cartilage repair and Epicel for extensive burns. Vericel also holds North American rights to development-stage NexoBrid.
Key Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Total revenue | $117.9 million | $90.9 million | +29.7% |
| MACI revenue | $91.6 million | $67.7 million | +35.2% |
| Epicel revenue | $26.2 million | $23.1 million | +13.5% |
| Gross profit | $80.3 million | $58.7 million | +36.8% |
| Gross margin | 68.1% | 64.6% | +350 basis points |
| Operating loss | $11.3 million | $3.9 million | Higher loss |
| Net loss | $9.7 million | $8.1 million | Higher loss |
| Basic and diluted loss per share | $0.22 | $0.20 | Higher loss per share |
| Cash used in operating activities | $7.2 million | $0.4 million | Higher use |
| Cash, cash equivalents and investments | $78.9 million | $82.9 million | Down from prior year |
Cash and cash equivalents were $26.9 million, short-term investments were $42.8 million, and long-term investments were $9.2 million at December 31, 2019. Working capital was $91.9 million. Total liabilities were $42.1 million and shareholders’ equity was $111.1 million. The company had no outstanding debt following repayment of approximately $17.1 million of borrowings in December 2018.
Net loss included a $17.5 million upfront payment for the NexoBrid license, recorded as research and development expense. Research and development expense increased to $30.4 million from $13.6 million, while selling, general and administrative expense increased to $61.1 million from $49.0 million. Stock-based compensation rose to $13.2 million from $7.2 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by higher MACI implant volume and continued Epicel demand.
- Gross margin improved because revenue increased against a largely fixed manufacturing cost base.
- Operating and net losses increased despite revenue growth, primarily because of the NexoBrid upfront license payment, higher sales-force and marketing costs, patient reimbursement support costs, and stock-based compensation.
- MACI sales-force staffing increased from 40 to 48 representatives in 2019, with plans to expand to 76 representatives in 2020.
- Operating cash usage increased principally because of the NexoBrid payment, higher accounts receivable, inventory growth, and lease-related cash payments.
- Following the 2018 debt repayment, 2019 interest expense was immaterial and there were no outstanding warrants at year-end.
- Adoption of the new lease accounting standard brought approximately $25.1 million of right-of-use assets and $27.7 million of operating lease liabilities onto the year-end balance sheet; the filing states that adoption had an immaterial effect on earnings and cash flows.
- Quarterly results remained highly seasonal. 2019 revenue was $21.8 million in the first quarter, $26.2 million in the second, $30.5 million in the third, and $39.4 million in the fourth.
Guidance, Outlook, Risks and Unusual Items
- Management targeted submission of a BLA for NexoBrid to the FDA around mid-2020. Approval, timing, market acceptance, and commercialization remain uncertain.
- Management planned further MACI sales-force expansion to reach additional general orthopedic surgeons and stated its objective of generating positive operating income by growing commercial expenses more slowly than revenue.
- Management stated that existing cash, cash equivalents, and investments should fund current operations for at least 12 months after issuance of the financial statements. It does not currently anticipate needing equity financing at current revenue levels, but additional capital could be required if revenue declines or development needs increase.
- Vericel remains loss-making, with an accumulated deficit of approximately $378.7 million at year-end, and cautioned that it may not achieve or sustain profitability.
- U.S. commercial manufacturing for MACI and Epicel depends on a single Cambridge, Massachusetts facility. Damage, regulatory action, quality problems, or operational disruption could materially impair product supply.
- The company relies on third-party suppliers, including a sole supplier for the MACI collagen membrane, creating supply interruption and qualification risks.
- Revenue and receivables depend on third-party reimbursement. The MACI allowance for uncollectible consideration was $3.9 million at year-end; a 0.5% change in the estimated uncollectible percentage could change 2019 revenue by approximately $0.5 million.
- MACI faces competition from microfracture, osteochondral allografts, tissue products, and emerging cartilage-repair technologies. Epicel faces competition from other burn-treatment approaches, including RECELL for certain indications.
- NexoBrid obligations include a $7.5 million payment upon U.S. BLA approval, up to $125 million of sales milestones, and tiered royalties on net sales. These milestone payments were not considered probable or recorded as commitments at year-end.
- The filing reports no material legal proceedings and no material off-balance-sheet arrangements. PricewaterhouseCoopers issued an unqualified audit opinion and concluded that internal control over financial reporting was effective.
Most Important Facts for Investors to Verify
- Whether MACI volume growth and the planned sales-force expansion translate into sustained revenue growth and improved operating leverage.
- The timing, acceptability, regulatory review, and potential approval of the NexoBrid BLA, including remaining clinical and manufacturing requirements.
- Whether cash generation improves after the nonrecurring NexoBrid upfront payment and whether existing liquidity remains sufficient without equity dilution.
- The sustainability of the 68.1% gross margin as production volume, reimbursement, pricing, and manufacturing costs change.
- The accuracy and aging of MACI reimbursement-related receivables and contractual allowance estimates.
- Business-continuity plans for the single Cambridge manufacturing facility and mitigation of sole-source supplier exposure.
- The effect of stock-based compensation, which represented $13.2 million of 2019 expense and contributed to shareholder dilution.
- Potential future NexoBrid milestone, royalty, supply, and BARDA-related obligations.